Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Capricor Therapeutics' stock surged 500% after its Duchenne muscular dystrophy drug met key trial goals, reversing an earlier FDA rejection.

flag Capricor Therapeutics' stock soared up to 500% after its Phase 3 HOPE-3 trial for Deramiocel, a cell therapy for Duchenne muscular dystrophy, met its primary and secondary endpoints, showing significant improvement in heart function. flag The positive results reversed a previous setback when the FDA rejected its approval application in July 2024. flag The company immediately launched a public equity offering to leverage the renewed investor confidence. flag Meanwhile, NEXTDC signed a deal with OpenAI to build a hyperscale AI campus in Sydney, boosting its shares 8% amid optimism over Australia’s sovereign AI infrastructure. flag In mining, Critical Resources advanced its Cap Burn and Amoco projects in New Zealand and Australia, with promising drill results and plans for expanded exploration.

3 Articles